Nifty
:
22458.00
Sensex
:
74076.22
90.00 (0.40%)
337.77 (0.46%)
Nifty
Sensex
:
:
22458.00
74076.22
90.00 (0.40%)
337.77 (0.46%)

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
64/99

BSE: 524816 | NSE: NATCOPHARM

NSE BSE
1022.80
23-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1013.00
  •  1034.70
  •  1005.00
  •  1005.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  639513
  •  6512.41
  •  1108.35
  •  563.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 18,305.92
  • 14.33
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,825.22
  • 0.54%
  • 3.32

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 49.71%
  • 1.96%
  • 20.61%
  • FII
  • DII
  • Others
  • 16.14%
  • 9.66%
  • 1.92%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.87
  • 5.27
  • 9.67

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.66
  • 2.78
  • 8.59

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 21.42
  • 2.11
  • 17.50

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.83
  • 26.24
  • 27.27

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.46
  • 3.20
  • 3.12

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.30
  • 19.18
  • 20.65

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
758.60
492.50
54.03%
1,031.40
432.10
138.69%
1,140.50
884.60
28.93%
897.90
596.80
50.45%
Expenses
490.50
386.60
26.88%
573.40
336.80
70.25%
612.50
489.30
25.18%
558.80
615.40
-9.20%
EBITDA
268.10
105.90
153.16%
458.00
95.30
380.59%
528.00
395.30
33.57%
339.10
-18.60
-
EBIDTM
35.34%
21.50%
44.41%
22.06%
46.30%
44.69%
37.77%
-3.12%
Other Income
37.00
20.80
77.88%
29.40
20.50
43.41%
19.70
34.30
-42.57%
29.00
13.80
110.14%
Interest
4.60
3.80
21.05%
4.20
3.80
10.53%
4.20
4.20
0.00%
2.70
6.70
-59.70%
Depreciation
44.20
41.50
6.51%
43.60
41.70
4.56%
43.50
39.60
9.85%
41.00
38.10
7.61%
PBT
256.30
81.40
214.86%
439.60
70.30
525.32%
500.00
385.80
29.60%
324.40
-49.60
-
Tax
43.60
19.10
128.27%
70.60
13.50
422.96%
79.70
65.40
21.87%
48.60
0.90
5,300.00%
PAT
212.70
62.30
241.41%
369.00
56.80
549.65%
420.30
320.40
31.18%
275.80
-50.50
-
PATM
28.04%
12.65%
35.78%
13.15%
36.85%
36.22%
30.72%
-8.46%
EPS
11.88
3.41
248.39%
20.61
3.11
562.70%
23.48
17.56
33.71%
15.11
-2.77
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
3,828.40
2,707.10
1,944.80
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
Net Sales Growth
59.12%
39.20%
-5.23%
7.16%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
 
Cost Of Goods Sold
832.40
583.20
528.40
483.70
354.40
332.70
411.10
599.10
341.10
242.37
233.23
Gross Profit
2,996.00
2,123.90
1,416.40
1,568.40
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
GP Margin
78.26%
78.46%
72.83%
76.43%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
Total Expenditure
2,235.20
1,795.40
1,681.30
1,448.30
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
Power & Fuel Cost
-
81.90
76.40
61.10
62.40
59.60
56.20
50.50
43.70
43.24
44.77
% Of Sales
-
3.03%
3.93%
2.98%
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
Employee Cost
-
486.70
444.80
414.90
375.00
355.90
325.60
243.20
189.60
136.92
112.77
% Of Sales
-
17.98%
22.87%
20.22%
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
Manufacturing Exp.
-
279.60
353.60
165.70
243.30
276.40
182.60
141.20
105.20
73.04
76.57
% Of Sales
-
10.33%
18.18%
8.07%
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
General & Admin Exp.
-
208.80
152.80
242.90
132.60
126.40
105.50
88.10
73.40
63.66
56.21
% Of Sales
-
7.71%
7.86%
11.84%
6.92%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
Selling & Distn. Exp.
-
96.10
43.70
34.40
98.10
90.00
136.90
143.20
91.60
37.36
26.16
% Of Sales
-
3.55%
2.25%
1.68%
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
Miscellaneous Exp.
-
59.10
81.60
45.60
66.60
58.70
38.50
71.50
24.10
15.31
26.16
% Of Sales
-
2.18%
4.20%
2.22%
3.48%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
EBITDA
1,593.20
911.70
263.50
603.80
582.60
794.80
928.40
683.40
272.60
213.38
179.33
EBITDA Margin
41.62%
33.68%
13.55%
29.42%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
Other Income
115.10
128.50
99.00
106.00
107.40
130.20
40.40
13.90
9.90
14.91
16.71
Interest
15.70
14.50
17.70
13.30
21.50
19.30
15.40
18.50
22.90
31.68
36.62
Depreciation
172.30
163.80
142.60
116.90
99.80
81.00
66.20
54.40
51.00
47.27
30.44
PBT
1,520.30
861.90
202.20
579.60
568.70
824.70
887.20
624.40
208.60
149.34
128.98
Tax
242.50
146.60
32.20
137.20
110.60
182.30
192.00
139.50
52.80
3.95
30.87
Tax Rate
15.95%
17.01%
15.92%
23.67%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
PAT
1,277.80
715.30
170.00
440.90
460.80
644.40
696.20
486.00
157.10
134.62
102.74
PAT before Minority Interest
1,277.80
715.30
170.00
442.40
458.10
642.40
695.20
484.90
155.80
130.27
98.11
Minority Interest
0.00
0.00
0.00
-1.50
2.70
2.00
1.00
1.10
1.30
4.35
4.63
PAT Margin
33.38%
26.42%
8.74%
21.49%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
PAT Growth
228.48%
320.76%
-61.44%
-4.32%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
 
EPS
71.35
39.94
9.49
24.62
25.73
35.98
38.87
27.14
8.77
7.52
5.74

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
4,873.80
4,263.60
4,121.60
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
Share Capital
36.50
36.50
36.50
36.40
36.50
36.90
34.90
34.80
33.23
33.07
Total Reserves
4,837.30
4,223.70
4,067.60
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
Non-Current Liabilities
100.50
135.10
142.90
117.80
83.40
47.10
37.70
28.00
119.23
150.67
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
94.03
92.20
Unsecured Loans
0.00
0.00
0.00
0.90
0.00
0.00
0.00
0.00
2.99
3.28
Long Term Provisions
85.30
95.70
99.60
90.20
71.00
32.40
21.90
12.50
9.50
11.09
Current Liabilities
683.10
710.40
525.60
685.30
728.70
592.00
626.50
493.10
413.74
312.28
Trade Payables
263.80
161.80
146.20
255.40
217.00
269.10
262.70
275.60
125.30
109.79
Other Current Liabilities
227.30
126.70
99.50
95.90
109.80
133.40
127.10
114.20
118.56
102.18
Short Term Borrowings
165.00
404.00
265.80
315.00
386.30
173.20
221.60
98.40
168.54
98.63
Short Term Provisions
27.00
17.90
14.10
19.00
15.60
16.30
15.10
4.90
1.33
1.69
Total Liabilities
5,657.40
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
Net Block
2,426.90
2,311.80
2,023.20
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
Gross Block
3,375.10
3,126.90
2,702.10
2,148.70
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
Accumulated Depreciation
948.20
815.10
678.90
564.30
467.30
389.00
325.70
273.20
225.82
171.11
Non Current Assets
2,657.10
2,622.40
2,447.10
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
Capital Work in Progress
64.30
129.50
223.40
518.00
637.60
480.00
336.30
211.80
128.96
123.78
Non Current Investment
87.30
104.40
151.90
83.60
19.90
8.10
0.10
0.10
1.57
1.57
Long Term Loans & Adv.
78.30
72.00
44.30
72.00
62.80
75.40
60.40
62.10
57.03
54.25
Other Non Current Assets
0.30
4.70
4.30
4.20
8.40
2.30
0.50
0.60
3.54
3.24
Current Assets
3,000.30
2,486.70
2,344.80
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
Current Investments
305.00
203.70
151.80
28.70
148.70
68.40
32.10
22.10
0.12
0.32
Inventories
742.90
762.00
798.20
558.00
529.00
438.40
348.90
357.30
220.00
181.12
Sundry Debtors
856.10
620.60
412.90
551.30
506.20
637.50
475.20
261.60
192.43
118.80
Cash & Bank
546.30
206.10
283.50
66.00
279.50
183.70
35.80
45.20
13.36
11.05
Other Current Assets
550.00
88.10
94.70
91.60
883.80
802.70
195.30
150.80
57.06
56.85
Short Term Loans & Adv.
485.60
606.20
603.70
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
Net Current Assets
2,317.20
1,776.30
1,819.20
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
Total Assets
5,657.40
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
849.10
46.50
298.80
417.30
668.80
463.60
345.80
112.20
92.67
144.03
PBT
861.90
202.20
579.60
568.70
824.70
887.20
624.40
208.60
134.22
128.98
Adjustment
102.00
123.90
62.10
54.00
14.30
75.60
100.20
90.50
68.14
65.72
Changes in Working Capital
62.70
-231.40
-212.90
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
Cash after chg. in Working capital
1,026.60
94.70
428.80
525.10
847.60
668.20
471.60
158.40
116.41
178.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-177.50
-48.20
-130.00
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-477.10
-5.30
-103.30
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
Net Fixed Assets
-113.40
-204.80
-250.20
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
Net Investments
-107.50
-213.00
-145.90
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
Others
-256.20
412.50
292.80
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
Cash from Financing Activity
-363.00
34.80
-185.70
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
Net Cash Inflow / Outflow
9.00
76.00
9.80
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
Opening Cash & Equivalents
111.10
25.80
19.80
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
Closing Cash & Equivalent
131.90
111.10
25.80
19.80
28.30
21.70
23.50
-74.20
12.44
10.22

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
267.06
233.44
224.88
206.04
189.49
165.22
93.63
73.91
50.91
219.48
ROA
13.29%
3.43%
9.43%
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
ROE
15.66%
4.06%
11.27%
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
ROCE
18.06%
4.86%
13.99%
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
Fixed Asset Turnover
0.89
0.76
0.86
1.07
1.47
1.72
1.93
1.23
0.95
0.96
Receivable days
93.53
85.10
84.44
93.77
91.36
92.22
65.12
70.27
67.76
60.90
Inventory Days
95.32
128.47
118.77
96.38
77.28
65.25
62.41
89.35
87.33
80.17
Payable days
133.18
106.38
151.52
65.96
72.53
81.42
78.30
85.42
73.36
74.09
Cash Conversion Cycle
55.67
107.20
51.68
124.19
96.11
76.05
49.23
74.21
81.73
66.99
Total Debt/Equity
0.03
0.09
0.06
0.08
0.11
0.06
0.14
0.09
0.37
0.33
Interest Cover
60.44
12.42
44.58
27.45
43.73
58.61
34.75
10.11
5.24
4.52

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Natco Pharma gets warning letter from USFDA for Telangana plant
    9th Apr 2024, 17:16 PM

    A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

    Read More
  • Natco Pharma - Quarterly Results
    14th Feb 2024, 14:08 PM

    Read More
  • Natco Pharma invests around $2 million in Cellogen Therapeutics
    17th Jan 2024, 17:35 PM

    Cellogen is primarily involved in two R&D programs involving cell and gene therapy solutions

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.